Compare
BioNexus Gene Lab Corp vs American Shared Hospital Services vs CapForce Inc. vs Exagen Inc.
| Latest fiscal year | BioNexus Gene Lab Corp BGLC | American Shared Hospital Services AMS | CapForce Inc. CFOR | Exagen Inc. XGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $7.42M | $28.08M | $30.20M | $66.58M |
| Revenue growth (YoY) | -21.9% | -0.9% | +481.2% | +19.7% |
| Gross margin | 14.6% | 18.0% | n/a | 58.3% |
| Operating margin | -39.9% | -12.8% | 79.6% | -21.1% |
| Net margin | -40.2% | -5.5% | 78.2% | -30.0% |
| Net income | -$2.98M | -$1.55M | $23.62M | -$19.95M |
| EPS (Diluted) | n/a | -$0.23 | $2.32 | -$0.93 |
| Operating cash flow | -$1.84M | $3.10M | -$1.18M | -$13.62M |
| Free cash flow | -$1.88M | -$4.54M | -$1.23M | -$14.27M |
| Cash & equivalents | $2.49M | $3.46M | $531.3K | $32.22M |
| Total assets | $9.25M | $55.48M | $38.06M | $58.02M |
| Total liabilities | $637.9K | $27.79M | $6.20M | $40.57M |
| Shareholders' equity | $8.61M | $27.69M | $31.86M | $17.45M |
| Return on year-end equity | -34.6% | -5.6% | 74.1% | -114.3% |
| Shares outstanding | 2.42M | 6.58M | 10.15M | 22.91M |
Revenue, most recent five fiscal years
| Fiscal year | BioNexus Gene Lab Corp | American Shared Hospital Services | CapForce Inc. | Exagen Inc. |
|---|---|---|---|---|
| Latest | $7.42M Ended 2025-12-31 | $28.08M Ended 2025-12-31 | $30.20M Ended 2025-12-31 | $66.58M Ended 2025-12-31 |
| 1 year earlier | $9.51M Ended 2024-12-31 | $28.34M Ended 2024-12-31 | $5.20M Ended 2024-12-31 | $55.64M Ended 2024-12-31 |
| 2 years earlier | $9.77M Ended 2023-12-31 | $21.32M Ended 2023-12-31 | $3.42M Ended 2023-12-31 | $52.55M Ended 2023-12-31 |
| 3 years earlier | $10.93M Ended 2022-12-31 | $19.75M Ended 2022-12-31 | $2.61M Ended 2022-12-31 | $45.56M Ended 2022-12-31 |
| 4 years earlier | $13.36M Ended 2021-12-31 | $17.63M Ended 2021-12-31 | $4.31M Ended 2021-12-31 | $48.30M Ended 2021-12-31 |